BRAIN ACCESS
Live / Registered — Registered (as of 10 Jan 2023)
What this means for you
Registered since 10 Jan 2023. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 90042690
- Registration number
- 6945464
- Mark type
- Stylized text
- Filed
- 08 Jul 2020
- Published for opposition
- 25 Oct 2022
- Registered
- 10 Jan 2023
- Attorney of record
- M. SCOTT ALPRIN
Goods and services
- Class 001 — Chemicals: Chemicals, namely, chemicals for in vivo industrial use for analyzing the central nervous system; chemicals used in industry for in vivo analysis of the central nervous system
- Class 005 — Pharmaceuticals: Pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for the treatment of central nervous system diseases; pharmaceutical preparations for the treatment of central nervous system disorders; pharmaceutical preparations for the prevention of central nervous system diseases; pharmaceutical preparations for the prevention of central nervous system disorders; pharmaceutical preparations for the treatment of dementia, Alzheimer's disease, schizophrenia, depressive disorder, depression, and autism spectrum disorder; pharmaceutical preparations for the prevention of dementia, Alzheimer's disease, schizophrenia, depressive disorder, depression, and autism spectrum disorder; pharmaceutical preparations for the brain for the treatment of central nervous system diseases; pharmaceutical preparations for the brain for the treatment of central nervous system disorders; pharmaceutical preparations for the brain for the prevention of central nervous system diseases; pharmaceutical preparations for the brain for the prevention of central nervous system disorders; pharmaceutical preparations for the brain for treatment of dementia, Alzheimer's disease, schizophrenia, depressive disorder, depression, and autism spectrum disorder; pharmaceutical preparations for the brain for the prevention of dementia, Alzheimer's disease, schizophrenia, depressive disorder, depression, and autism spectrum disorder; pharmaceutical preparations for drug delivery systems which deliver medicament for the brain into the brain for the treatment of central nervous system diseases; pharmaceutical preparations for drug delivery systems which deliver medicament for the brain into the brain for the treatment of central nervous system disorders; pharmaceutical preparations for drug delivery systems which deliver medicament for the brain into the brain for the prevention of central nervous system diseases; pharmaceutical preparations for drug delivery systems which deliver medicament for the brain into the brain for the prevention of central nervous system disorders; pharmaceutical preparations for drug delivery systems which deliver medicament for the brain into the brain for the treatment of dementia, Alzheimer's disease, schizophrenia, depressive disorder, depression, and autism spectrum disorder; pharmaceutical preparations for drug delivery systems which deliver medicament for the brain into the brain for the prevention of dementia, Alzheimer's disease, schizophrenia, depressive disorder, depression, and autism spectrum disorder; dietary supplements for humans; dietary supplements for animals; in vivo diagnostic agents for medical purposes specifically for analyzing the central nervous system; radio-isotope markers for therapeutic or in vivo diagnostic use
- Class 040 — Treatment of materials: Custom manufacture of pharmaceuticals; processing of medicinal materials; Custom manufacture of chemicals, except for chemicals for in vitro diagnostic use
- Class 042 — Scientific and technological services: Testing, inspection or research of pharmaceuticals, chemicals or cosmetics, except for chemicals for in vitro diagnostic use; testing the functionality of machines, except for machines for in vitro diagnostic use; research on machines, except for machines for in vitro diagnostic use
Owner
- Braizon Therapeutics, Inc., Bunkyo-ku, Tokyo, JP
- Braizon Therapeutics, Inc., Bunkyo-ku, Tokyo, JP
- Braizon Therapeutics, Inc., Bunkyo-ku, Tokyo, JP
Prosecution history
- 10 Jan 2023 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 10 Jan 2023 — REGISTERED-PRINCIPAL REGISTER
- 25 Oct 2022 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 25 Oct 2022 — PUBLISHED FOR OPPOSITION
- 05 Oct 2022 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 22 Sept 2022 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 22 Sept 2022 — EXAMINER'S AMENDMENT ENTERED
- 22 Sept 2022 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 22 Sept 2022 — EXAMINERS AMENDMENT E-MAILED
- 22 Sept 2022 — EXAMINERS AMENDMENT -WRITTEN
- 21 Sept 2022 — ASSIGNED TO EXAMINER
- 21 Sept 2022 — PREVIOUS ALLOWANCE COUNT WITHDRAWN
- 21 Sept 2022 — ASSIGNED TO EXAMINER
- 21 Sept 2022 — WITHDRAWN FROM PUB - MANAGING ATTORNEY REQUEST
- 20 Sept 2022 — CASE RETURNED TO EXAMINATION